Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Vivus Inc (VVUS)

Vivus Inc (VVUS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Global $4.7 Billion Erectile Dysfunction Market Outlook and Forecast 2021-2026: Major Players are Eli Lilly and Co, VIVUS, Pfizer, Bayer, Boston Scientific, Coloplast, Teva, Viatris, Dong-A Socio

The "Erectile Dysfunction Market - Global Outlook and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

BSX : 39.53 (+2.01%)
VVUS : 0.4665 (-10.29%)
VIVUS Receives Court Approval of Joint Chapter 11 Plan of Reorganization

VIVUS, Inc. (the "Company"), a biopharmaceutical company, today announced that it has received approval from the United States Bankruptcy Court for the District of Delaware (the "Bankruptcy Court") on...

VVUS : 0.4665 (-10.29%)
VIVUS Seeks Bankruptcy Court Approval of Second Amended Joint Chapter 11 Plan of Reorganization and Existing Stock Record Date

On November 10, 2020, VIVUS, Inc. (the "Company"), a biopharmaceutical company, filed the Second Amended Joint Prepackaged Chapter 11 Plan of Reorganization of VIVUS, Inc. and Its Affiliated Debtors [Docket...

VVUS : 0.4665 (-10.29%)
Delisting of Securities of KemPharm, Inc.; Endologix, Inc.; VIVUS, Inc.; SAExploration Holdings, Inc.; Ascena Retail Group, Inc.; and Global Eagle Entertainment Inc. from The Nasdaq Stock Market

The Nasdaq Stock Market announced today that it will delist the common stock of KemPharm, Inc. KemPharm, Inc.'s common stock was suspended on May 21, 2020 and has not traded on Nasdaq since that time....

ASNA : 0.6063 (-15.67%)
ELGX : 0.2200 (-23.88%)
KMPH : 9.52 (-3.94%)
NDAQ : 141.99 (+1.18%)
SAEX : 0.3000 (-51.61%)
VVUS : 0.4665 (-10.29%)
VIVUS Announces Updated Agreement with Icahn Enterprises Holdings L.P.

VIVUS, Inc. (Nasdaq: VVUS; the "Company"), a biopharmaceutical company, today announced that it has updated its agreement regarding its corporate debt with Icahn Enterprises Holdings L.P. (dba IEH Biopharma...

VVUS : 0.4665 (-10.29%)
Vivus: 1Q Earnings Snapshot

CAMPBELL, Calif. (AP) _ Vivus Inc. (VVUS) on Wednesday reported a loss of $5.2 million in its first quarter.

VVUS : 0.4665 (-10.29%)
VIVUS Reports First Quarter 2020 Financial Results

Company to host conference call today at 4:30pm ET

VVUS : 0.4665 (-10.29%)
VIVUS to Host First Quarter Business Update and Financial Results Conference Call on Wednesday, May 6, 2020

VIVUS, Inc. (Nasdaq: VVUS) today announced that it will report financial results and provide a business update for the first quarter of 2020 after the market close on Wednesday, May 6, 2020. The Company...

VVUS : 0.4665 (-10.29%)
VIVUS Announces Agreement with IEH Biopharma LLC Granting the Company a 30-Day Grace Period to Restructure its Corporate Debt

VIVUS, Inc. (Nasdaq: VVUS; the "Company"), a biopharmaceutical company, today announced an agreement regarding its corporate debt with IEH Biopharma LLC, which holds a principal amount of approximately...

VVUS : 0.4665 (-10.29%)
VIVUS Announces Closing of $11.55 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

VIVUS, Inc. (Nasdaq: VVUS; the "Company"), a biopharmaceutical company, today announced the completion of its previously announced registered direct offering of 7,218,750 shares of the Company's common...

VVUS : 0.4665 (-10.29%)
VitalTech Partners with VIVUS Pharmaceuticals to Accelerate Launch of Telehealth and Remote Patient Monitoring Modules

VitalTech, a rapidly growing market leader in Virtual Care, announced today its partnership with VIVUS, Inc, a publicly held biopharmaceutical company (Nasdaq: VVUS). Leveraging VitalTech's industry-leading...

VVUS : 0.4665 (-10.29%)
VIVUS Announces $11.55 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

VIVUS, Inc. (Nasdaq: VVUS; the "Company"), a biopharmaceutical company, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase...

VVUS : 0.4665 (-10.29%)
5 Best Penny Stocks To Buy This Week?

CORAL GABLES, FL / ACCESSWIRE / March 31, 2020 / The top website for all things penny stocks, PennyStocks.com just released a new, exclusive & informative article titled: . The team at PennyStocks.com...

VVUS : 0.4665 (-10.29%)
VIVUS Accelerates the Launch of Telemedicine and Remote Monitoring Modules to Facilitate Effective Patient Care During "Social Distancing"

Virtual office visits and smart health devices available through the VIVUS Health Platform give physicians new tools for optimizing patient care and protecting the health of those at increased risk for...

VVUS : 0.4665 (-10.29%)
Vivus: 4Q Earnings Snapshot

CAMPBELL, Calif. (AP) _ Vivus Inc. (VVUS) on Tuesday reported a loss of $6.5 million in its fourth quarter.

VVUS : 0.4665 (-10.29%)
VIVUS Reports Fourth Quarter and Full Year 2019 Financial Results

- Company to host conference call today at 4:30pm ET -

VVUS : 0.4665 (-10.29%)
VIVUS Completes Enrollment in Phase 4 Safety and Efficacy Study of Qsymia(R) in Adolescents

-Post-marketing study designed to evaluate Qsymia as an approach to weight management in a growing patient population with significant unmet medical need-

VVUS : 0.4665 (-10.29%)
VIVUS Announces Commercial Launch of Qsymia(R) in the Republic of Korea Establishing New Royalty Revenue Stream

- VIVUS to Receive Milestone Payment from Alvogen; Significant Worldwide Growth Potential for Qsymia -

VVUS : 0.4665 (-10.29%)
VIVUS to Host Fourth Quarter Business Update and Financial Results Conference Call on Tuesday, March 3, 2020

VIVUS, Inc. (Nasdaq: VVUS) today announced that it will report financial results and provide a business update for the fourth quarter of 2019 after the market close on Tuesday, March 3, 2020. The company...

VVUS : 0.4665 (-10.29%)
VIVUS Receives U.S. Food and Drug Administration Approval for Improved Formulation of PANCREAZE(R) with a 36-Month Shelf Life

VIVUS, Inc. (Nasdaq: VVUS) ("VIVUS"), a biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for an improved...

VVUS : 0.4665 (-10.29%)

Van Meerten Stock Picks

5 Great Small Caps
Summary 100% technical buy signals.
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar